A Tirol-based MedTech startup focused on early detection and risk prediction of women’s cancers using epigenetic diagnostics. Its first product, the WID-easy Test, is a molecular PCR test that detects endometrial cancer from a simple self-collected vaginal swab. The company licenses its technology to partner laboratories and has expanded availability to the DACH region and the UK.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €2.2 M | Sep, 2025 | grant |
Industries
Frequently Asked Questions
Where is Sola Diagnostics located?
Sola Diagnostics is located in Innsbruck, Austria.
What industries does Sola Diagnostics operate in?
Sola Diagnostics operates in the following industries: medtech, diagnostics, women's health, oncology, genomics, epigenetics.
When was Sola Diagnostics founded?
Sola Diagnostics was founded on 2025-09-30.
How much total funding has Sola Diagnostics raised?
Sola Diagnostics has raised a total of $2,200,000.
Who are the investors in Sola Diagnostics?
The investors in Sola Diagnostics are: Undisclosed UK grant provider.
What is the primary purpose of the WID-easy test offered by Sola Diagnostics?
The WID-easy test is an epigenetic diagnostic tool designed for the early detection of uterine cancer, specifically for women experiencing abnormal bleeding during or after menopause.
How is the Sola Diagnostics WID-easy test performed?
The procedure is non-invasive and involves a simple vaginal swab, similar to a cervical screening. The collected sample is analyzed in a laboratory using PCR technology to identify specific DNA methylation patterns.
Who is the ideal candidate for Sola Diagnostics testing?
The testing is primarily recommended for peri-menopausal and post-menopausal women who experience abnormal uterine bleeding, which can be an early indicator of uterine cancer.
What are the main benefits of using Sola Diagnostics tests over traditional ultrasound?
These tests significantly reduce false positive results compared to transvaginal ultrasound, helping many women avoid unnecessary and invasive diagnostic procedures like hysteroscopy or biopsies.
In which countries can patients currently access Sola Diagnostics tests?
The diagnostic services are currently offered by laboratories and clinics in Austria, Switzerland, and the United Kingdom.
Does Sola Diagnostics testing provide reliable results across different ethnic groups?
Clinical data shows that the testing performs with high sensitivity and accuracy across all ethnic groups, helping to provide more equitable diagnostic outcomes for all women.